Sugi Predict

Sugi Predict / Compounds / SCHEMBL294877

SCHEMBL294877

SCHEMBL294877

COC(=O)c1ccc(OC)cc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ ALK Q9UM73 1/20 0.42
▸ HPGD P15428 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NR4A2 P43354 1/20 0.42
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974920 0.94 HSD11B1 (0.45) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL3187945 0.90 KMT2A (0.45) KDM4EGLAGAAHSD17B10KMT2A
SCHEMBL17080255 0.89 KDM4E (0.48) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL903987 0.89 KDM4E (0.45) KDM4EKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL7530260 0.88 ALDH1A1 (0.46) KMT2ASMN1; SMN2ALDH1A1CXCR2HSD11B1
SCHEMBL14063330 0.87 HSD11B1 (0.46) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL26619763 0.84 CA12 (0.51) KDM4EGAAHSD17B10SMN1; SMN2MAPT
SCHEMBL6643810 0.84 HSP90AA1 (0.43) KDM4EHSD17B10HPGDSMN1; SMN2ALDH1A1
SCHEMBL4634289 0.84 FFAR4 (0.52) KDM4EHSD17B10SMN1; SMN2NPC1RAB9A
SCHEMBL6637191 0.84 L3MBTL1 (0.44) KDM4ECYP1A2CYP2C19HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113013366-B Organic electroluminescent element, display device, lighting device, and anthracene compound 学校法人关西学院 2024-03-26 — — CN disclosed
US-11647666-B2 Organic electroluminescent element KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) 2023-05-09 — — US disclosed
US-11647666-B2 Organic electroluminescent element KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) 2023-05-09 — — US disclosed
US-11647666-B2 Organic electroluminescent element KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) 2023-05-09 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
CN-110692146-B Organic electroluminescent element, and display device or lighting device 学校法人关西学院（JP） 2023-01-13 — — CN disclosed
CN-110249442-B Compound (I) 学校法人关西学院 2022-11-22 — — CN disclosed
CN-110291652-B Organic electroluminescent element, display device, lighting device, and compound 学校法人关西学院 2022-05-17 — — CN disclosed
CN-113906036-A Polycyclic aromatic compound 学校法人关西学院 2022-01-07 — — CN disclosed
US-11139438-B2 Organic electroluminescent element KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) 2021-10-05 — — US disclosed
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-16 — — US disclosed
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-02 — — US disclosed
US-6342765-B1 COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS ASTRAZENECA UK LIMITED (GB) 2002-01-29 — — US disclosed
WO-2001097810-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-12-27 — — WO disclosed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 — — EP disclosed
EP-1025088-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ASTRAZENECA AB (SE) 2001-09-05 — — EP disclosed
WO-2001046138-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE ASTRAZENECA AB (SE) 2001-06-28 — — WO disclosed
EP-1025088-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS AstraZeneca UK Limited (GB) 2000-08-09 — — EP disclosed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 — — WO disclosed
WO-1999020611-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1999-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 KDM4E 1741/4885CYP1A2 1361/4885CYP2D6 1475/4885
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA KDM4E 3060/4885CYP1A2 543/4885CYP2D6 687/4885
US-11139438-B2 Organic electroluminescent element ELP1, NFE2L2, ESR2 KDM4E 1620/4885CYP1A2 293/4885CYP2D6 632/4885
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA KDM4E 3247/4885CYP1A2 667/4885CYP2D6 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.